Close

After-Hours Movers: Novavax Sinks Over 30%, GoodRx and Lemonade Climb

August 8, 2022 5:15 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

GoodRx Holdings, Inc. (NASDAQ: GDRX) +34%; Revenue for the quarter came in at $191.8 million versus the consensus estimate of $185.36 million.

Lemonade (NYSE: LMND) +13%; reported Q2 EPS of ($1.10), $0.23 better than the analyst estimate of ($1.33). Revenue for the quarter came in at $50 million versus the consensus estimate of $47.56 million.GUIDANCE: Lemonade sees Q3 2022 revenue of $63-65 million, versus the consensus of $56.98 million. Lemonade sees FY2022 revenue of $236-239 million, versus the consensus of $214.67 million.

Bed Bath & Beyond (NASDAQ: BBBY) +9%; extends earlier gain after meme stocks bid higher.

CorMedix (NASDAQ: CRMD) -58%; today announced updates related to the FDA review of the DefenCath New Drug Application (NDA) as well as other manufacturing and commercial updates. A second Complete Response Letter (CRL) was received from the FDA stating that the DefenCath NDA cannot be approved until deficiencies recently conveyed to the contract manufacturing organization (CMO) and the supplier of the active pharmaceutical ingredient (API) heparin during inspections are resolved to the satisfaction of FDA.

Novavax (NASDAQ: NVAX) -32%; Novavax (NASDAQ: NVAX) reported Q2 EPS of ($6.53), $12.03 worse than the analyst estimate of $5.50. Revenue for the quarter came in at $186 billion versus the consensus estimate of $1.02 billion. GUIDANCE: Novavax sees FY2022 revenue of $2-2.3 billion, versus the consensus of $4.27 billion.

TaskUs, Inc. (NASDAQ: TASK) -16%; reported Q2 EPS of $0.38, $0.05 better than the analyst estimate of $0.33. Revenue for the quarter came in at $246.5 million versus the consensus estimate of $242.11 million. GUIDANCE: TaskUs, Inc. sees Q3 2022 revenue of $224-226 million, versus the consensus of $244 million. TaskUs, Inc. sees FY2022 revenue of $930-950 million, versus the consensus of $992 million.

CarGurus (NASDAQ: CARG) -15%; reported Q2 EPS of $0.32, $0.01 better than the analyst estimate of $0.31. Revenue for the quarter came in at $511.2 million versus the consensus estimate of $507.32 million. GUIDANCE: CarGurus sees Q3 EPS of $0.25-$0.28, versus the consensus of $0.33. CarGurus sees Q3 revenue of $460-490 million, versus the consensus of $554.6 million.

3D Systems (NYSE: DDD) -13% ; reported Q2 EPS of ($0.07), $0.07 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $140 million versus the consensus estimate of $146.8 million. GUIDANCE: 3D Systems sees 2022 revenue of $530-570 million, versus the consensus of $598 million.

Allbirds, Inc. (NASDAQ: BIRD) -13%; reported Q2 EPS of ($0.12), $0.04 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $78.2 million versus the consensus estimate of $77.8 million. GUIDANCE: Allbirds, Inc. sees FY2022 revenue of $305-315 million, versus the consensus of $339.6 million.

Trex (NYSE: TREX) -12%; reported Q2 EPS of $0.79, $0.12 better than the analyst estimate of $0.67. Revenue for the quarter came in at $386 million versus the consensus estimate of $381.1 million. GUIDANCE: Trex sees Q3 2022 revenue of $185-195 million, versus the consensus of $354.82 million. Trex sees FY2022 revenue of $1.09-1.11 billion, versus the consensus of $1.38 billion.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

After-Hours Movers, FDA